Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-22
2006-08-22
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07094786
ABSTRACT:
Methods are disclosed for the treatment of nausea and vomiting in a patient suffering therefrom comprising administering 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine.
REFERENCES:
patent: 4695568 (1987-09-01), Ninomiya et al.
patent: 4753789 (1988-06-01), Tyers et al.
patent: 4783478 (1988-11-01), Wootton et al.
patent: 4845092 (1989-07-01), Sanger et al.
patent: 4939136 (1990-07-01), Haeck et al.
patent: 5225407 (1993-07-01), Oakley et al.
patent: 5352685 (1994-10-01), Maruyama et al.
patent: 5470868 (1995-11-01), Young
patent: 5530008 (1996-06-01), Azcona et al.
patent: 5576317 (1996-11-01), Gonsalves
patent: 5663343 (1997-09-01), van der Meij et al.
patent: 5945415 (1999-08-01), Kato et al.
patent: 5962494 (1999-10-01), Young
patent: 5977127 (1999-11-01), Bonnacker et al.
patent: 5985866 (1999-11-01), Müller et al.
patent: 5990159 (1999-11-01), Meulemans et al.
patent: 6054461 (2000-04-01), Fairbanks et al.
patent: 6117879 (2000-09-01), Fairbanks et al.
patent: 6156771 (2000-12-01), Rubin et al.
patent: 6284770 (2001-09-01), Mangel et al.
patent: 6355647 (2002-03-01), Steiner et al.
patent: 6376550 (2002-04-01), Raber et al.
patent: 6429209 (2002-08-01), Mangel et al.
patent: 6440453 (2002-08-01), Fischer et al.
patent: 6441038 (2002-08-01), Loder et al.
patent: 6465458 (2002-10-01), Wong et al.
patent: 6552045 (2003-04-01), Rubin et al.
patent: 6593336 (2003-07-01), Mangel et al.
patent: 2001/0020025 (2001-09-01), Megens
patent: 2001/0044450 (2001-11-01), Mangel et al.
patent: 2002/0002197 (2002-01-01), Mueller et al.
patent: 2002/0086880 (2002-07-01), Rubin et al.
patent: 2002/0086881 (2002-07-01), Rubin et al.
patent: 2002/0107244 (2002-08-01), Howard, Jr.
patent: 2003/0036500 (2003-02-01), Rubin et al.
patent: 2003/0036549 (2003-02-01), Mangel et al.
patent: 2003/0158221 (2003-08-01), Zhang et al.
patent: 2003/0203055 (2003-10-01), Rao et al.
patent: 2004/0048874 (2004-03-01), Bardsley et al.
patent: 2004/0254171 (2004-12-01), Landau et al.
patent: 0 313 393 (1994-03-01), None
patent: 0216027.3 (2002-07-01), None
patent: 0220064.0 (2002-08-01), None
patent: 0304648.9 (2003-02-01), None
patent: 0316115.5 (2003-07-01), None
patent: 06016557 (1994-01-01), None
patent: WO 94/01095 (1994-01-01), None
patent: WO 98/50037 (1998-11-01), None
patent: WO 99/02516 (1999-01-01), None
patent: WO 00/06160 (2000-02-01), None
patent: WO 00/51583 (2000-09-01), None
patent: WO 00/51584 (2000-09-01), None
patent: WO 01/41748 (2001-06-01), None
patent: WO 02/44170 (2002-06-01), None
patent: WO 02/094249 (2002-11-01), None
patent: WO 03/061657 (2003-07-01), None
patent: WO 03/077897 (2003-09-01), None
patent: WO 2004/004734 (2004-01-01), None
patent: WO 2004/019948 (2004-03-01), None
patent: WO 2004/058353 (2004-07-01), None
Angel, I., et al. “Litoxetine: A Selective 5-HT Uptake Inhibitor with Concomitant 5-HT3Receptor Antagonist and Antiemetic Properties,”Eur. J. Pharmacol., 232(2-3):139-145 (1993).
Béïque, J.C., et al., “Affinities of Venlafaxine and Various Reuptake Inhibitors for the Serotonin and Norepinephrine Transporters,”Eur. J. Pharmacol., 349(1): 129-132 (1998).
Burns, M.J., “The Pharmacology and Toxicology of Reboxetine,”Int. J. Med. Toxicol.3(4):26 1-8 (2000).
Butler, A., et al, “Pharmacological Properties of GR38032F, a Novel Antagonist at 5-HT3Receptors,”Br. J. Pharmacol., 94(2): 397-412 (1988).
Bymaster, F.P., et al., “Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine TransportersIn VitroandIn Vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors,”Neuropsychopharmacology, 25(6):871-880 (2001).
Camilleri, M., “Serotonergic Modulation of Visceral Sensation: Lower Gut.”Gut51(1):81-86 (2002).
Center for Drug Evaluation and Research Application No.: 020623; Pharmacology Reviews; Jul. 5, 1996.
Crow, M.K., et al. “Management of Nausea and Vomiting,”Medical Oncology: A Comprehensive Review, [Retrieved Jan. 29, 2003] Retrieved from the Internet <URL:http://www.cancernetwork.com/textbook/morev41.htm>.
Depoortere, I., et al., “Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis1, ”J. Pharmacol. Exp. Ther., 294(3): 983-990 (2000).
Eguchi, J., et al, “Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)thieno-[2,3-d]pyrimidine Monodydrate Hydrocloride,”Arzneim-Forschung/Drug Res., 47(12): 1337-1347 (1997).
Eguchi, J., et al., “The Anxiolytic-Like Effect of MCI-225, A Selective NA Reuptake Inhibitor with 5-HT3Receptor Antagonism,”Pharm. Biochem. and Behavior, 68:677-683 (2001).
Fairweather, D. B., et al., “The Psychomotor and Cognitive Effects of Litoxetine in Young and Middle Aged Volunteers,”Br. J. Clin. Pharmacol., 40(2):119-125 (1995).
Ito, C., et al., “Effect of GK-128 [2-[(2-Methylimidazol-1-yl]- benzo[f]thiochromen-1-one Monohydrochloride Hemihydrate], a Selective 5-Hydroxytryptamine3Receptor Antagonist, on Colonic Function in Rats,”J. Pharmacol. Exp. Ther., 280(1): 67-72 (1997).
Jin, J.G., et al., “Propulsion in Guinea Pig Colon Induced by 5-Hydroxytryptamine (HT) Via 5-HT4and 5-HT3Receptors1,”J. Pharmacol. Exp. Ther.,288(1): 93-97 (1999).
Kilpatrick, G., et al., “Identification and Distribution of 5-HT3Receptors in Rat Brain Using Radioligand Binding,”Nature, 330: 746-748 (1987).
Kuver, R., et al., “Nausea and Vomiting in Adolescents and Adults,”Nausea and Vomiting, [Retrieved Jan. 29, 2003] Retrieved from the Internet <URL:http://www.uwgi.org/cme/cmeCourseCD/ch—01/ch01txt.htm>.
Ladabaum, U. and Hasler, W.L., “Novel Approaches to the Nausea and Vomiting,”Dig. Dis.,17(3): 125-132 (1999).
LOTRONEX—Tablets,Product Information, GlaxoSmithKline, Research Triangle Park, NC, pp. 1-13 (2002).
Milano, S. et al., “The Piglet as a Suitable Animal Model for Studying the Delayed Phase of Cisplatin-Induced Emesis,”J. Pharmacol. Exp. Ther., 274(2): 951-961 (1995).
Million, M., et al., “Susceptibility of Lewis and Fischer Rats to Stress-induced Worsening of TNB-colitis: Protective Role of Brain CRF,”Amer. Phys. Soc.,276 (4 Pt 1): G1027-G1036 (1999).
Morrow, G.R., et al., “Progress in Reducing Nausea and Emesis,”Cancer76(3): 343-357 (1995).
Owens, M.J., et al., “Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and their Metabolites1,”J. Pharmacol. Exp. Ther.,283(3): 1305-1322 (1997).
Prakash, C., et al., “Tricyclic Antidepressants for Functional Nausea and Vomiting: Clinical Outcome in 37 Patients,”Dig. Dis. Sci., 43(9):1951-1956 (1998).
Prakash, C. and Clouse, R.E., “Cyclic Vomiting Syndrome in Adults: Clinical Features and Response to Tricyclic Antidepressants,”Am. J. Gastroenterol., 94(10):2855-2860 (1999).
Sallan, S.E., et al., “Antiemetics in Patients Receiving Chemotherapy for Cancer,”N. Eng. J. Med.,302(3): 135-138 (1980).
Spiller, R., “Pharmacotherapy: Non-serotonergic Mechanisms”Gut,51 (Suppl 1): i87-90 (2002).
Venkova, K. et al., “Peripheral Activity of a New NK1Receptor Antagonist TAK-637 in the Gastrointestinal Tract,”J. Pharmacol. Exp. Ther., 300(3): 1046-1052 (2002).
Veyrat-Follet, C., et al., “Physiology of Chemotherapy-Induced Emesis and Antiemetic Therapy,”Drugs53(2): 206-234 (1997).
Wong, E.H.F., et al., “Reboxetine: A Pharmacologically Potent, Selective, and Specific Norepinephrine Reuptake Inhibitor,”Biol. Psychiatry.47(9): 818-829 (2000).
Wood, J.D., et al. “Fundamentals of Neurogastroenterology,”Gut45(2):II6-II16 (1999).
Landau Steven B.
Miller Cheryl L.
Thor Karl B.
Dynogen Pharmaceuticals, Inc.
Jones Day
Spivack Phyllis G.
LandOfFree
Method of treating nausea, vomiting, retching or any... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating nausea, vomiting, retching or any..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating nausea, vomiting, retching or any... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3647851